Update on pharmacogenetics in cancer chemotherapy

被引：65

作者：

Innocenti, F ^{[1
]}

Ratain, MJ ^{[1
]}

机构：

[1] Univ Chicago, Dept Med, Ctr Canc Res, Comm Clin Pharmacol & Pharmacogenom, Chicago, IL 60637 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷 / 05期

关键词：

cancer; chemotherapy; pharmacogenetics; toxicity; response;

D O I：

10.1016/S0959-8049(01)00434-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This review describes how genetic differences among patients may change the therapeutic outcome in cancer chemotherapy. Severe toxicity in genetically predisposed patients is predominantly associated with mutations in drug metabolism enzyme genes, and an update on genetic intolerance to 6-mercaptopurine, 5-fluorouracil, and irinotecan is provided. Moreover, recent findings pointed out that the methylenetetrahydrofolate reductase (MTHFR) C677T mutation might change patient susceptibility to the toxic effects of the cyclophosphamide, methotrexate, 5-fluorouracil (CMF) regimen and raltitrexed. Finally, it is emerging that not only toxicity, but also response to chemotherapy could be influenced by pharmacogenetic determinants, and the clinical relevance of polymorphisms in thymidylate synthase (TS) and glutathione-S-transferase (GST) genes is discussed. (C) 2002 Elsevier Science Ltd. All rights reserved.

引用

页码：639 / 644

页数：6

共 60 条

[1] Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese [J].